目的 了解2011-2016年成都地區(qū)21家醫(yī)院抗腫瘤靶向藥物的使用情況及變化趨勢(shì)，為臨床合理用藥提供參考。方法 對(duì)成都地區(qū)21家醫(yī)院2011-2016年抗腫瘤靶向藥物的銷售金額、用藥頻度（DDDs）、日均費(fèi)用（DDC）進(jìn)行統(tǒng)計(jì)分析。結(jié)果 2011-2016年成都地區(qū)21家醫(yī)院抗腫瘤靶向藥物的使用金額波動(dòng)較大，2013年使用金額最大，2015年降至最低；曲妥珠單抗、吉非替尼和索拉菲尼的使用金額大幅降低，伊馬替尼的使用金額呈不斷增加趨勢(shì)。曲妥珠單抗、吉非替尼和厄洛替尼的DDDs大幅降低，伊馬替尼的DDDs急劇增加?？鼓[瘤靶向藥物的DDC整體波動(dòng)較小，美妥昔單抗的DDC最高，其次為西妥昔單抗。結(jié)論 成都地區(qū)21家醫(yī)院抗腫瘤靶向藥物的使用合理，符合安全、有效、經(jīng)濟(jì)、方便原則。

Objective To investigate the utilization and trend of anti-tumor targeted drugs in 21 hospitals in Chengdu area from 2011 to 2016, and to provide a reference for clinical drug use. Methods Consumption sums, defined daily dose (DDDs), and average daily cost (DDC) of anti-tumor targeted drugs in 21 hospitals in Chengdu area from 2011 to 2016 were comprehensively analyzed. Results Consumption sums of anti-tumor targeted drugs had larger fluctuation in 21 hospitals in Chengdu area from 2011 to 2016. Consumption sums in 2013 were the largest, while those in 2015 decreased to the lowest. Consumption sums of trastuzumab, gefitinib, and sorafenib were sharply decreased, while consumption sum of imatinib had an increasing trend. DDDs of trastuzumab, gefitinib, and erlotinib were sharply decreased, while DDDs of imatinib were sharply increased. DDC of anti-tumor targeted drugs had less fluctuation on the whole. DDC of metuximab was the biggest, and then was cetuximab. Conclusion The utilization of anti-tumor targeted drugs in 21 hospitals in Chengdu area is reasonable, according with the principle of safety, effectiveness, economy and convenience.